Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

APG350

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has raised attention as a novel anticancer therapeutic as it… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
No. 1702 AACR Annual Meeting 2017, April 1-5, Washington D.C. 1. Holland P.M. (2014) Death receptor agonist therapies for cancer… Expand
  • figure 5
Is this relevant?
2013
2013
Cancer cells can be specifically driven into apoptosis by activating Death-receptor-4 (DR4; TRAIL-R1) and/or Death-receptor-5… Expand
Is this relevant?
2013
2013
.................................................................................................................................................. 1 Sammendrag ............................................................................................................................................ 3 Acknowledgments ................................................................................................................................... 5 Table of 
  • figure 1.1
  • figure 1.2
  • figure 1.3
  • figure 1.4
  • figure 1.5
Is this relevant?
2013
2013
Cancer cells can be specifically driven into apoptosis by activating Death-receptor-4 (DR4; TRAIL-R1) and/ or Death-receptor-5… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
APG350 is a TRAIL-receptor (TRAIL-R) agonist comprising two single-chain TRAIL-R binding domains (scTRAIL-RBD) that are dimerized… Expand
Is this relevant?
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL TRAIL (Apo2L) is a member of the Tumor Necrosis Factor… Expand
Is this relevant?